Form 4: Amylyx Pharmaceuticals CEO Sells Shares
Insider Transaction (Form 4)
Justin B. Klee, Co-Chief Executive Officer and a Director of Amylyx Pharmaceuticals, Inc., sold 30,464 shares of common stock on September 10, 2026.
Summary
- Open-market sale: disposed of 29,025 Common Stock at $32.13 ($932,553) on September 10, 2026; holds 3,614,495 after (Direct).
- Open-market sale: disposed of 1,439 Common Stock at $33.16 ($47,710) on September 10, 2026; holds 3,613,056 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $980,263 of stock on the open market.
Insider Transactions
Justin B. Klee — Director, Officer (Co-Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Open-market sale | Common Stock | 29,025 | $32 | $932.6K | 3,614,495 |
| 2026-09-10 | Open-market sale | Common Stock | 1,439 | $33 | $47.7K | 3,613,056 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Open-market sale (29,025 shares) |
| 2026-09-10 | Open-market sale (1,439 shares) |
Keywords
insider transaction, Form 4, AMLX, Amylyx Pharmaceuticals, Inc., bearish, Justin B. Klee
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.